Hypertension Conferences | Cardiology Events | Netherlands | Europe | USA

Theme: New insights in diagnosis and management for hypertension

Hypertension 2017

Conference Program

Renowned Speakers

Peter de Leeuw
Maastricht University Medical Center
Netherlands

Pieter Doevendans
University Medical Center Utrecht
Netherlands

Asher Kimchi
Cedars-Sinai Heart Institute
USA

Stamatios Lerakis
Emory Heart and Vascular Center
USA

Jose Antonio F. Ramires
University of SÃ£o Paulo
Brazil

Louis Peeters
Utrecht University
Netherlands

Hans Duvekot
Erasmus University
Netherlands

Hossein Tabriziani
Loma Linda University
USA

Marc Spaanderman
Maastricht University
Netherlands

ValÃ©ria Paula S. Fazan
University of SÃ£o Paulo
Brazil

Sokolovic Sekib
University Clinical Center Sarajevo and Medical
Bosnia and Herzegovina

Bertram Pitt
University of Michigan School of Medicine
USA

Hypertension 2017

Hypertesnion 2017 is proud to host CME Accredited Event 2^nd International Conference on Hypertension & Healthcare during the beautiful month of September 11-13, 2017 at Amsterdam, Netherlands, the place which sees the largest influx of tourists in Amsterdam. Working under the theme “New insights in diagnosis and management for hypertension” we bring together the brightest and most productive minds to discuss the intricate concepts of Hypertension diagnosis and management.

The conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical professionals like Directors, Heads, Deans, Professors, Scientists, Researchers, Cardiologists and Writers of the Hypertension or Cardiology and related departments, Founders and Employees of the related companies, Associations, Organizations, Laboratory members and Young researchers working in the field of hypertension treatment and management. This conference mainly focuses on spreading the awareness about challenges in this field and how to prevent and manage hypertension.

CME Credits by Spanish Society of Cardiology & ACCME :

The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits .

In support of improving patient care, this activity has been planned and Center for Education Development (CED). CED is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Center for Education Development designates the live format for this educational activity for AMA PRA Category 1 Credits™ and ANCC credit. Participants should only claim credit commensurate with the extent of their participation in the activity. Full accreditation information including disclosures, credit hours available and faculty information will be provided in the attendee hand-out onsite.

Why to attend??

Encounter the target market with members from across the globe, committed to learn about hypertension treatment and management. This is the best opportunity to outreach the largest gathering of participants from around the world. Conduct presentations, distribute and update knowledge about the current situation of hypertension treatment and receive name recognition at this 3-day event. World-eminent speakers, most recent researches, latest treatment techniques and the advanced updates in Hypertension Management are the principal features of this conference.

Target Audience:

Our Organization would be privileged to welcome the:

Directors of Hypertension or related Programs or Associations
Heads, Deans and Professors of Hypertension or Cardiology and related departments
Scientists and Researchers
Doctors
Writers
Founders and Employees of the related companies
Hypertension Associations and Organizations
Laboratory members and Students working in the field of hypertension treatment and management

Encouraged with the success of Hypertension Conference Series, we bring up the CME Accredited Event 2^nd International Conference on Hypertension & Healthcare. With its powerful 3 day agenda Hypertension 2017 is designed to take place at the beautiful Netherlands in the Amsterdam city during September 11-13, 2017.

We focus on bringing together world’s most productive visionaries, professors, cardiologists and leading researchers to share their research works and results in the field of Hypertension. Take a deep dive into the newest technologies made in the field with the edifying talks of our Speakers which will help in broadening your horizons.

Hypertension 2017 is an international platform for presenting research about Hypertension and related concepts, sharing alternative ideas about the severe cardiovascular risk factor, thus contributing to the dissemination of information about the trouble for the welfare of the society. This event enables its patrons to showcase their research works in front of Speakers, Delegates and Attendees from vastly different areas across the Globe.

The conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical professionals like Directors, Heads, Deans, Professors, Scientists, Researchers, Cardiologists and Writers of the Hypertension or Cardiology and related departments, Founders and Employees of the related companies, Associations, Organizations, Laboratory members and Young researchers working in the field of hypertension treatment and management. This conference mainly focuses on spreading the awareness about challenges in this field and how to prevent and manage hypertension.

Track 1: Hypertension

Hypertension, also known as high blood pressure or arterial hypertension is a chronic medical condition in which the blood pressure in the arteries is elevated. This session mainly covers the different types of hypertension and their assessment. There are two primary hypertension types. For 95% of people with high blood pressure, the cause of their hypertension is unknown — this is called essential or primary hypertension. When a cause can be found, the condition is called secondary. Isolated systolic hypertension, malignant hypertension, and resistant hypertension are all recognized hypertension types with specific diagnostic criteria.

A sphygmomanometer (sfig-mo-ma-NOM-e-ter) is the instrument that measures blood pressure. It consists of an inflatable cuff, or wide band, that is wrapped around the upper arm, a rubber bulb to inflate the cuff, and a device that gives the pressure reading.

Assessment of hypertension basically includes: Confirmation of hypertension, Risk factors, Underlying causes, End organ damage & Indications and contraindications for antihypertensive drugs.

Hypertension is a major risk factor for heart diseases and stroke. Globally, the overall prevalence of raised blood pressure in adults aged 25 and over was around 40% in 2008. Because of population growth and ageing, the number of people with uncontrolled hypertension rose from 600 million in 1980 to nearly 1 billion in 2008.The national Million Hearts initiative endeavours to increase the number of persons whose hypertension is under control, by 10 million, as part of its goal to prevent 1 million heart attacks and strokes by the year 2017.
The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

19^th Annual Cardiology Conference, August 31-September 01, 2017, Philadelphia, USA; 2^nd International Conference on Non-invasive Cardiac Imaging, Nuclear Cardiology & Echocardiography, September 11-12, 2017, Amsterdam, Netherlands; 20^th European Cardiology Conference, October 16-18, 2017, Budapest Hungary; 21st International Conference on Clinical & Experimental Cardiology, November 06-07, 2017 Las Vegas, USA; 22^nd World Cardiology Conference, December 11-12, 2017, Rome, Italy; Cardio Rhythm 2017 February 24 – 26 2017, Hong Kong; American Cardiology Association conference March 17-19, 2017, USA 7th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus, March 2-5, 2017, Cannes, France ; 4^th World Congress on Acute Heart Failure, April 29-May 02, 2017, Paris, France; European Congress of Preventive Cardiology 2017, April 06-08, 2017, Malaga, Spain; BCS Annual Conference, June 05-07, 2017, Manchester; 27th European Meeting on Hypertension and Cardiovascular Protection, June 16-19, Milan, Italy; 2017 Congress on CVD Prevention, September 15-17, 2017.

Related Societies:

American Society of Hypertension; International Society of Hypertension; European Society of Hypertension; British Hypertension Society; Hypertension Canada; American College of Cardiology; Asian Pacific Society of Hypertension; Brazilian Society of Hypertension; German Hypertension Society; High Blood Pressure Research Council of Australia; International Society for the Study of Hypertension in Pregnancy; Latin American Society of Hypertension; Swedish Society of Hypertension, Stroke and Vascular Medicine; Turkish Society of Hypertension and Atherosclerosis; World Heart Federation; World Hypertension League; South Africa Society for Cardiovascular Research; Chinese Society of Cardiology; Indonesian Heart Association; National Heart Association of Malaysia; Cardiometabolic Heart Congress; Heart Rhythm Society; Japanese Circulation Society; Asian Pacific Society of Cardiology; American Heart Association; Heart Failure Society of America; Society for Cardiovascular Angiography and Interventions.

Track 2: Hypertension & Obesity

Hypertension (high blood pressure) refers to the pressure that blood applies to the inner walls of the arteries. Obesity increases the risk of the development of hypertension. The respective session mainly focuses on obesity-related hypertension, its interaction with the outcomes of hypertension, risk factors, treatment and management of obesity induced hypertension.

Obesity-associated arterial hypertension is characterized by activation of the sympathetic nervous system, activation of the renin-angiotensin system, and sodium retention, among other abnormalities. It is estimated that excess body weight, accounted for approximately 26% of cases of hypertension in men and 28% in women and for approximately 23% of cases of coronary heart disease in men and 15% in women. Obese individuals have an increase in fatty tissue that increases their vascular resistance and in turn increases the work the heart has to do to pump blood throughout the body. Indicators for risk of hypertension include obesity, abdominal obesity and weight gain.

Anti-hypertension medications should be started if hypertension is diagnosed. But, with weight-loss, a significant fall in blood pressure may permit a decrease in the number of medications taken or decrease the amount of medication taken. Prevention would be better than any drug.

Given the important pathophysiologic links between weight and hypertension described, a significant increase in the prevalence of hypertension in coming years could be expected, if trends of increasing weight in the population are not stabilized and reversed. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 3: Renal Hypertension

Renal hypertension, also called renovascular hypertension, is elevated blood pressure caused by kidney disease. It is a syndrome which consists of high blood pressure caused by the kidneys' hormonal response to narrowing of the arteries supplying the kidneys (renal artery stenosis). When functioning properly this hormonal axis regulates blood pressure. Due to low local blood flow, the kidneys mistakenly increase blood pressure of the entire circulatory system. It is a form of secondary hypertension a form of hypertension whose cause is identifiable. This session mainly accounts for the various causes and symptoms of renovascular hypertension, along with its pathogenesis, diagnosis and treatment.

High blood pressure is dangerous partly because the patients generally do not experience the symptoms, so organ damage can occur slowly without being recognized. Renal hypertension can cause chronic kidney disease. Various techniques have been developed to diagnose renal hypertension using digital image processing of radiographs. Medications are used first to try to control high blood pressure in renal hypertension. In some people with renal hypertension due to narrowing of the renal artery, even taking three or more medications every day may not adequately control blood pressure. In these situations, a procedure like angioplasty or stenting, to improve blood flow to the kidneys can often help.

Its prevalence is 2% in those who have a diastolic blood pressure of more than 100 mmHg and approximately 30% in patients who have diastolic blood pressure more than 130mmHg. Patients with renal hypertension are at increased risk of end organ dysfunction, including permanent kidney damage, if inadequate pharmacologic therapies are used to control blood pressure. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 4: Pulmonary Hypertension

Pulmonary hypertension (PH) is an increase of blood pressure in the pulmonary artery, pulmonary vein, or pulmonary capillaries, leading to shortness of breath, dizziness, fainting, leg swelling and other symptoms. Having pulmonary arterial hypertension (PAH) means that one has a high blood pressure in the arteries that go from the lungs to heart. Symptoms of pulmonary hypertension do not usually occur until the condition has progressed. The first symptom of pulmonary hypertension is usually shortness of breath with everyday activities, such as climbing stairs. Fatigue, dizziness, and fainting spells also can be symptoms. The molecular mechanism of pulmonary arterial hypertension (PAH) is not known yet, but it is believed that the endothelial dysfunction results in a decrease in the synthesis of endothelium-derived vasodilators such as nitric oxide and prostacyclin. Diagnosis of the severe heart condition includes mainly Echocardiography or as per the signs and symptoms of the condition.

The various related issues with Pulmonary Hypertension include HIV Associated Pulmonary Hypertension, Liver Disease and Pulmonary Hypertension and PH in Association with Sickle Cell Disease.

Idiopathic pulmonary arterial hypertension is a rare disease with an incidence of about 2-3 cases per million per year and a prevalence of about 15 per million. Adult females are almost three times more likely to be present with IPAH than adult males. The presentation of IPAH within children is more evenly split along gender lines. Up to 4% of people who suffer a pulmonary embolism go on to develop chronic thromboembolic disease including pulmonary hypertension. Levels of mortality are very high in pregnant women with severe pulmonary hypertension. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 5: Gestational Hypertension

Gestational hypertension or pregnancy-induced hypertension (PIH) is the development of new hypertension in a pregnant woman after 20 weeks gestation without the presence of protein in the urine or other signs of Pre-eclampsia in pregnancy. It is a temporary diagnosis for hypertensive pregnant women who do not meet criteria for preeclampsia or chronic hypertension (hypertension first detected before the 20^th week of pregnancy). The diagnosis is changed to, Preeclampsia, if proteinuria or new signs of end-organ dysfunction develop and chronic (primary or secondary) hypertension, if blood pressure elevation persists ≥12 weeks postpartum.

The risk factors for Gestational hypertension comprise maternal causes like obesity, past history or adolescent pregnancy, multiple gestations, and family history. There is no specific treatment, but it is monitored closely to rapidly identify pre-eclampsia and its life-threatening complications. Drug treatment options are limited, as many antihypertensive drugs may negatively affect the foetus. During gestational hypertension a women must be offered an integrated package of care, covering admission to hospital, treatment, measurement of blood pressure, testing for proteinuria and blood tests.

Gestational hypertension in a future pregnancy ranges from about 1 in 8 (13%) pregnancies to about 1 in 2 (53%) pregnancies. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 6: Hypertension & Stroke

Hypertension is the most prevalent and powerful modifiable risk factor for stroke, irrespective of geographic region and ethnic group. Persons with hypertension are about 3 or 4 times more likely to have a stroke. Whereas diastolic BP was once thought to be the most important predictor of stroke, the relationship between stroke and hypertension may be stronger for systolic than for diastolic BP. The association between BP and stroke risk seems to occur on a continuum rather than as a threshold effect. Major strokes have been reported among persons with only “borderline” or “mild” hypertension, and both persons classified as “hypertensive” as well as “normotensive” could have the benefit of BP lowering. Therefore, although the highest BP levels predict the highest relative risk of stroke, the conceptual pendulum has swung in the direction of the continuum of absolute BP levels and somewhat away from the construct of “hypertension” per se. Furthermore, as discussed below, recent evidence points to the fact that mediators of hypertension, such as Ang II, may influence stroke risk independently of Blood pressure elevation.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 7: Causative Factors and Risk Assessment

High Blood Pressure has many causative factors such as age, race, family history, obesity, not being physically active, consuming tobacco, too much salt (sodium) in diet, too little potassium and vitamin D in diet, drinking too much alcohol, stress and certain chronic conditions. There are general risk factors that can be responsible for raising anyone's risk of hypertension. Although high blood pressure is most common in adults, children may be at risk, too. For some children, high blood pressure is caused by problems with the kidneys or heart. But for a growing number of kids, poor lifestyle habits, such as an unhealthy diet, obesity and lack of exercise, contribute to high blood pressure. Sometimes pregnancy contributes to high blood pressure, as well. Certain diseases and medications are specific causes of high blood pressure.

Cardiovascular disease represents the leading cause of morbidity and mortality in Western countries, and hypertension-related cardiovascular events or hypertensive emergencies affect about 37 million people per year, worldwide. In this perspective, hypertensive patients are at increased risk to experience cardiovascular events during life-long period, and treatment of high blood pressure represents one of the most effective strategies to reduce global cardiovascular risk. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 8: Diagnosis and Pathophysiology of Hypertension

Hypertension, or high blood pressure, is the leading risk factor associated with death in the world but is largely asymptomatic and often undetected in patients. Hypertension is typically asymptomatic and only detected through opportunistic screening. Symptoms only manifest when blood pressure reaches very high levels (usually >200 mmHg systolic), and can include headache, dizziness and nose bleeding. It is usually diagnosed when a patient’s blood pressure is repeatedly found to be 140/90 mmHg or higher in a clinical setting and average readings taken using ambulatory blood pressure monitoring or monitoring at home are higher than 135/85 mmHg. Once hypertension has been diagnosed, further tests should be conducted, including urine testing, blood tests, an eye examination and a 12-lead electrocardiogram (ECG).Primary hypertension, in which no specific cause is found, affects 95% of patients.

Blood pressure is expressed in terms of systolic blood pressure (higher reading), which reflects the blood pressure when the heart is contracted (systole), and diastolic blood pressure (lower reading), which reflects the blood pressure during relaxation (diastole). Hypertension can be diagnosed when either systolic pressure, diastolic pressure, or both are raised.

Blood pressure is determined by the cardiac output balanced against systemic vascular resistance. The process of maintaining blood pressure is complex, and involves numerous physiological mechanisms, including arterial baroreceptors, the renin–angiotensin–aldosterone system, atrial natriuretic peptide, endothelins, and mineralocorticoid and glucocorticoid steroids. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 9: Pharmacologic and Other Treatments for Hypertension

Medications to treat high blood pressure includes Thiazide diuretics, Beta blockers, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Calcium channel blockers and Renin inhibitors. Additional medication sometimes used to treat high blood pressure comprises Alpha blockers, Alpha-beta blockers, Central-acting agents, Vasodilators and Aldosterone antagonists.

No matter what medications a doctor prescribes to treat high blood pressure, lifestyle changes are required to lower blood pressure. Eating a healthier diet with less, exercising regularly, quitting smoking, limiting the amount of alcohol, maintaining a healthy weight or losing weight must be followed up to control high blood pressure. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 10: Diet and Lifestyle in Hypertension Management

High blood pressure, which is also called hypertension, increases the risk of developing many serious health problems, including heart disease, stroke, and kidney disease. Evaluation and Treatment of High Blood Pressure recommendations have defined “hypertension” as a BP of ≥140/90 mm Hg. The risk of cardiovascular diseases in patients with hypertension can be greatly reduced with effective antihypertensive therapy.

Maintenance of normal body weight, following a proper diet plan, lifestyle modification including exercise, avoiding high-sodium content foods, limited alcohol consumption and appropriate medications as prescribed by the doctor may lead to a controlled and manageable blood pressure account. Also monitoring the blood pressure regularly may prevent hypertension and reduce the risk of high blood pressure-related health problems. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 11: Hypertension Epidemiology

Hypertension is a powerful risk factor for fatal and nonfatal cardiovascular disease events. Data from observational studies indicate that this risk is continuous, without evidence of a threshold, down to blood pressures as low as 115/75 mm Hg. Randomized controlled trials have convincingly shown that treatment of hypertension reduces the risk of stroke, coronary heart disease, congestive heart failure, and mortality. Various studies of hypertension control have been performed in a variety of epidemiological and practice settings.

Despite the recognition that diabetic persons are at especially high risk of cardiovascular disease, studies suggest that hypertension is as poorly controlled in diabetic persons as it is in non-diabetics. Chronic kidney disease represents another comorbidity associated with both difficult blood pressure control and high cardiovascular risk. Various patient characteristics have been associated with uncontrolled hypertension, including age, obesity, and lack of exercise. These characteristics are risk factors for hypertension itself and presumably contribute directly to difficult blood pressure control. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 12: Advanced Treatment Approaches

Treating high blood pressure can take a multi-pronged approach including diet changes, medication, and exercise. Hypertension, or high blood pressure, is dangerous because it can lead to strokes, heart attacks, heart failure, or kidney disease. The goal of hypertension treatment is to lower high blood pressure and protect important organs, like the brain, heart, and kidneys from damage. Treatment for hypertension has been associated with reductions in stroke (reduced an average of 35%-40%), heart attack (20%-25%), and heart failure (more than 50%), according to research.

Because hypertension rarely causes specific symptoms, it is not identified until an individual’s blood pressure is measured by a physician or it causes a catastrophic complication such as stroke or heart attack. Accurate diagnosis by blood pressure measurement is essential. Many advanced treatment approaches and medications have been established for the treatment and management of hypertension that may describe this session. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Events | Hypertension Conference

Related Societies:

Track 13: Clinical Case Reports

High blood pressure, also known as hypertension, affects millions -- even children and teens. It is a common condition that catches up with most people who live into older age. The exact cause of hypertension is unknown, but there are several factors and conditions that may contribute to its occurrence. About one in every four adults has hypertension.

High blood pressure is often called a "silent disease" because people usually don't know they have it; there may be no outward symptoms or a sign, so monitoring the blood pressure is critical. Treating high blood pressure can take a multi-pronged approach including diet changes, medication, and exercise. Hypertension treatment comes in many forms -- from lifestyle changes to medication.

Thus, case study on patients with different forms of Hypertension, may lead to a better way of improvement in emerging ideas or techniques for treating High Blood Pressure. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

Related Conferences: Cardiology Conferences | Cardiologists Meetings | CME Meetings | Hypertension Conference

Related Societies:

ConferenceSeries Ltd is glad to invite you to the CME Accredited Event “2^nd International Conference on Hypertension & Healthcare” to be held during September 11-13, 2017 at Amsterdam, Netherlands. The conference emphasizes the theme “New insights in diagnosis and management for hypertension” focusing on the latest ideas and advances for hypertension treatment and management. Hypertension 2017 event welcomes the innovative strategies in the area of hypertension research and also proposes a unique opportunity for the explorers from all over the world to gather, share and perceive new scientific interactions upon the various perceptions of hypertension. The Spanish Society of Cardiology Accreditation Committee (CASEC) is providing 16.3 CME Credits.

ConferenceSeries Ltd organizes 600+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

For more details please visit: http://hypertension.conferenceseries.com/

Conference Highlights:

Hypertension
Hypertension & Obesity
Renal Hypertension
Pulmonary Hypertension
Gestational Hypertension
Hypertension Risk Factors
Hypertension Diagnosis
Hypertensive Emergency
Hypertension Management
Hypertension Epidemiology
Advanced Treatment Approaches
Case Reports

Importance & Scope:

Hypertension is a major risk factor for cardiovascular diseases, cerebrovascular events and ischaemic heart diseases, so is therefore one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. It is often symptomless, so screening is vital before damage is done. Many surveys continue to show that hypertension remains underdiagnosed, undertreated and poorly controlled. Overall, the prevalence of hypertension (at least ≥140/90 mm Hg or on treatment) in those aged over 35 was observed to be 32% in men and 27% in women.

Blood Pressure has a skewed normal distribution within the population and the currently accepted model assumes risk is continuously related to BP. Essential hypertension (primary, cause unknown) accounts for the majority of cases, particularly in the older patient.

Hypertension 2017 is an international platform for presenting research about Hypertension and related concepts, sharing alternative ideas about the severe cardiovascular risk factor, thus contributing to the dissemination of information about the trouble for the welfare of the society.

Overall Prevalence of Hypertension Globally

Why Amsterdam:

Amsterdam is a good place for universities and cardiovascular research institutes like VU University Medical Canter, MRes Cardiovascular Research and more cardiology research centres with 3.6 percent of the GNP, Amsterdam makes the second highest investment in research and development in the country. About 61percent of R&D spending goes to the very pronounced publicly funded and university research landscape. Industry receives about a 27-percent share. Amsterdam is unique in that science as a resource is available to industrial companies in a highly compact manner and offers companies excellent cooperation opportunities.

Members Associated with Hypertension

There are 560 Cardiology Specialists near and 1000 Cardiology Specialists in Netherlands and 32, 000 Cardiology Specialists in worldwide.

Hospitals Associated with Hypertension

Amsterdam Hospitals

University Medical Center St. Radboud
Erasmus MC
University Medical Center Utrecht
Haven Hospital and Institute for Tropical Zietken
VU Medical Centre
Westeinde Hospital
University Medical Center St. Radboud

Netherlands Hospitals

St. Elizabeth’s Hospital
VU University Medical Center
Academic Medical Center
Medical Centre Alkmaar
St. Antonius Ziekenhuis Nieuwegein
St. Maarten Medical Center
Leiden University Medical Center
Ziekenhuis Amstelveen

Globe:

American Cardiology and Nuclear Practice
AMG Cardiovascular Consultants
BehringHospital Vall D'Hebron, Laboratorio ecocardiografia, Barcelona
Calvert Cardiology Clinic
Cardio Care, LLC
Cardiology and Internal Medicine PA
Cardiology Center
Cardiovascular Center Of Hagerstown
Cardiovascular Diagnostic Center, PA
Columbia Cardiac Care
Coronary Artery Disease NSC "The M. D. Strazhesko Institute of Cardiology" Kiev
Delmarva Heart, LLC’
Doctors Community Hospital
Suburban Cardiology and Internal Medicine, PC
Taunton Satellite Office
The Cambridge Hospital
The Heart Center of Metro West
The Plymouth Heart Center
Tufts Medical Center
UMass Memorial Health Care Cardiac Ultrasound Laboratory
UMass Memorial Medical Health Care-Memorial Campus
West Roxbury Veterans Affairs Medical Center
Whidden Hospital
Winchester Cardiac Ultrasound
Winchester Hospital Echocardiography Laboratory
WPA-Woburn Medical

Societies Associated with Hypertension

Amsterdam

European society of cardiology

Netherlands

Netherlands Society Hypertension
Netherlands Society of Cardiology
Dutch Society of Cardiology
The British Society of Amsterdam and the Netherlands

Globe:

Arun dal heart associates
Cardiology Associates, LLC Annapolis
Cardiology Associates, LLC Kent Island
Cardiovascular Specialists of Frederick
Chesapeake and Washington Heart Care, PC
Chesapeake Cardiovascular Associates- Woodholme
Child Cardiology Associates
Delaware Cardiovascular Associates Elkton Office
Patuxent Cardiology Associates
Steward Medical Group, LLC
Steward Physician Network, Inc.
Suburban Cardiology and Internal Medicine, PC
The Cardiovascular Specialists

Universities Associated with Hypertension

Amsterdam universities

University of Amsterdam
Academic Medical Center
VU University Amsterdam
Amsterdam University College
Amsterdam University of Applied Sciences
Vrije Universiteit Amsterdam
Webster University

Netherlands Universities

Heidelberg University
Pieter Nieuwland College
Bredero Beroepscollege
Utrecht University
University of Groningen
Radboud University Nijmegen
Wageningen University
Erasmus University Rotterdam
Tilburg University
Hogeschool van Amsterdam

Worldwide

Anglia Ruskin University
Arkansas Tech University
Canterbury Christ Church University
Colorado State University
Johns Hopkins University
Plymouth University
Stanford University
Swansea University
The University of Sydney
Ulster University
University of Leeds
University of Oxford

Industries Associated with Hypertension

Globe

Bausch + Lomb,
Bayer HealthCare Pharmaceuticals,
Berlin-Chemie, Biotronik,
opTec BerlinBrandenburg
Pfizer and Sanofi
OCEAN HEALTHCARE INDUSTRIES
CLINTON INDUSTRIES INC.

Global Market at a Glimpse:

High blood pressure or hypertension is the most important risk factor for cardiovascular disease.In over 90% of cases there may be no identifiable cause of hypertension, in which case the condition is known as essential hypertension. The remaining 10% of cases, hypertension may be secondary in nature as a consequence of another medical problem, such as kidney disorders, adrenal tumours, or some drugs. The prevalence of hypertension is forecasted to grow from 234 million in 2010 to 246 million in 2016 across the seven major markets (France, Germany, Italy, Spain, UK, US, and Japan). In 2016, the US is still expected to be the largest market for hypertension, with an anticipated 83 million sufferers, followed by Japan at 49 million. According to the International Society of Hypertension, there is a clear recognition of hypertension as a major public health issue across all the 7MM. The global cardiovascular market recorded a sale of $170bn in the year 2010 and is set to grow to $187bn in 2016 at a CAGR of 1.6%. The US continued to be the largest market, with a share of 40% of the overall market. Anti hypertensives remained the largest drug class in the year 2010, with a global sale of $37.6bn and a global market share of 22%. The global market for hypertension management devices is a variable and dynamic market that will experience a strong growth through the year 2023 as an increasing number of devices would become available to address a largely unmet clinical needs.

Products manufactured by the industry related Hypertension

My Lab™ Gamma’-
Multipurpose ultrasound imaging smart portable ultrasound system
Ultrasound transducer
Micro convex ultrasound
Pencil probe ultrasound
Transesophageal ultrasound transducer
FUJIFILM Medical Systems U.S.A., Inc.- latest version of Synapse Cardiovascular 6.0* and
Synapse 3D
HAUSMANN INDUSTRIES, INC.-Echo-Scan
Kontron

Kontron's Medical Computers enable sustainable and viable medical solutions for several applications.

Fund Allotment to Hypertension Research:

The NIH (National Institute of Health) Funding Opportunity Announcement (FOA), funded by the Patient-Centered Outcomes Research Institute (PCORI), funds up to two new patient-centred comparative effectiveness clinical trials, with the goal of comparing alternative, evidence-based ways to reduce inadequate control of hypertension and disparities in outcomes among high-risk populations, including racial/ethnic minority groups, patients with low socioeconomic status (SES), and individuals residing in rural geographical areas with an above average lifetime risk of cardiovascular disease (CVD). This initiative is supported by the Hypertension Disparities Reduction Program Partnership (HDRPP), a research partnership between NHLBI, NINDS and PCORI, with funds provided by PCORI to the NIH.

The fund allotment granted by the NIH is raised up to $21,500,000 worldwide for supporting research works associated with the advances in treatment and management of Hypertension

Statistics of Physicians, Researchers and Academicians working on Hypertension:

The estimated statistics of the number of physicians, academicians and researchers working upon the advancement in the treatment and management of hypertension are as described in the pie chart here in.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	September 11-13, 2017
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2	Day 3
Poster Opportunity Closed	Click Here to View